Cstone Submits Clinical Trial Application In Australia For CS5001 (ROR1 ADC) In Combination With First-Line Standard-Of-Care For DLBCL
Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming ...
Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
Managed Healthcare Executive16h
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
Finely tuned large language models can extract PD-L1 biomarker details from electronic health records
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
Le Lézard18h
Survey Reveals Perspectives on Maternal and Infant Immunizations; Gaps in Education and Information
A new survey from the National Coalition for Infant Health reveals levels of awareness about immunizations for pregnant women and newborns, including vaccines and long-acting preventive monoclonal ...
Le Lézard18h
123Invent Inventor Develops Protective Covers for Metal Weight Plates (SBT-2044)
"I'm an experienced weight lifter, and I wanted to create a bumper-like cover for use with metal weight plates," said an inventor, from McKinleyville, Calif., "so I invented the PLATE PROTECTOR. My ...
ImmunityBio Receives FDA RMAT Designation for ANKTIVA and CAR-NK (PD-L1 t-haNK) to Achieve Reversal of Lymphopenia in Pancreatic Cancer Patients
Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...
Pharmaceutical Technology on MSN21h
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
Oncology Nurse Advisor23h
Disitamab Vedotin Plus Toripalimab Demonstrates Activity in HER2-Expressing MIBC
Neoadjuvant disitamab vedotin plus perioperative toripalimab showed promising efficacy and acceptable safety in patients with HER2-expressing MIBC, according to Xinan Sheng, MD.